Quantitation of IgG subclass antibody responses after immunization with a group B meningococcal outer membrane vesicle vaccine, using monoclonal mouse-human chimeric antibodies as standards.
An ELISA method was developed to quantitate gravimetrically (microgram/ml) the IgG subclass response against a Norwegian vaccine composed of outer membrane vesicles (OMV) isolated from a Neisseria meningitidis B:15:P1.7,16 epidemic strain. Chimeric mouse-human anti-hapten NIP (5-iodo-4-hydroxy-3-nitrophenacetyl) antibodies of each subclass were used for calibration purposes. Before vaccination, low amounts of IgG1 and IgG2 antibodies against OMV were detectable in all vaccinees, whereas IgG3 was only detectable in one of the 21 vaccinees. After vaccination, IgG1 antibodies dominated the response followed by IgG3 and low to moderate levels of IgG2 antibodies. IgG4 was only detectable at very low levels in a few vaccinees. All sera showed close to parallel dose-response curves to each other for IgG1 and IgG3, whereas the IgG2 curves were not parallel to chimeric IgG2 and could thus not be quantitated gravimetrically. For IgG3, 1/3 of the vaccinee sera showed non-parallel dose-response curves to the rest of the vaccinee sera and to chimeric IgG3 and could not be gravimetrically quantitated. The rest of the sera showed parallel dose-response curves with the chimeric IgG3 and gravimetric quantitation was possible. This study illustrates that chimeric antibodies can be used as calibrators to quantitate IgG subclass antibody responses against OMV in gravimetric units and that the vaccine mainly induces IgG1 and IgG3 antibodies in humans.
Naess
L M
LM
Department of Vaccinology, National Institute of Public Health, Oslo, Norway.
Rosenqvist
E
E
Høiby
E A
EA
Michaelsen
T E
TE
D000328:Adult; D000818:Animals; D000907:Antibodies, Bacterial / Q000096:biosynthesis* / Q000145:classification* / Q000276:immunology; D000911:Antibodies, Monoclonal; D000918:Antibody Specificity; D001425:Bacterial Outer Membrane Proteins / Q000276:immunology*; D001428:Bacterial Vaccines / Q000276:immunology*; D006801:Humans; D007106:Immune Sera / Q000032:analysis; D007074:Immunoglobulin G / Q000096:biosynthesis* / Q000145:classification* / Q000276:immunology; D008297:Male; D051379:Mice; D009345:Neisseria meningitidis / Q000276:immunology*; D011993:Recombinant Fusion Proteins / Q000276:immunology* / Q000592:standards*; D012015:Reference Standards; D012680:Sensitivity and Specificity
D000907:Antibodies, Bacterial; D000911:Antibodies, Monoclonal; D001425:Bacterial Outer Membrane Proteins; D001428:Bacterial Vaccines; D007106:Immune Sera; D007074:Immunoglobulin G; D011993:Recombinant Fusion Proteins